Navigation Links
AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer
Date:10/22/2013

K inhibitor, which has been shown to be effective as monotherapy and in combination with standard chemotherapy regimens in Phase 1 and Phase 2 clinical studies across a range of solid tumors, which support the development of selumetinib in patients with MEK-dependent cancers.

MEK is part of the MAPK pathway which is frequently activated in cancer, and is elevated in many different solid tumors, including those featuring the KRAS mutation, which is present in 20% of human cancers and 20-30% of NSCLC tumors. 

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.   Novartis began Phase 3 trials evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and in patients with BRAF-mutant melanoma in October 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in August 2013 and began a Phase 3 trial in patients with non-small cell lung cancer in October 2013.  Two other wholly-owned drugs, ARRY-520 and ARRY-614, are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013.  For more information on Array, please go to www.arraybiopharma.com.

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, me
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
3. Omthera Stockholders Approve Acquisition by AstraZeneca
4. AstraZeneca Neuroscience partners with ePharmaSolutions to optimize Clinical Trial Management
5. Isis Pharmaceuticals Earns $6 Million Payment from AstraZeneca
6. Covington Advises Omthera Pharmaceuticals on Merger with AstraZeneca
7. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
8. AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation
9. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
10. Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
11. AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Ill. , Sept. 22, 2014  AbbVie ... from several clinical studies evaluating potential new medicines ... at the upcoming 2014 European Society of Medical ... Madrid, Spain . Data being presented ... the safety and efficacy of veliparib (ABT-888), a ...
(Date:9/22/2014)... DIEGO , Sept. 22, 2014 Arena Pharmaceuticals, ... company is scheduled to present a corporate overview and ... on Friday, September 26, 2014, at 11:30 a.m. Eastern ... Hotel in New York City . ... will be available under the investor relations section of ...
(Date:9/22/2014)... According to the new ... (Equipment, Media and Reagents), by Source, by type, ... Toxicity Testing, Research, Drug Discovery) - Analysis & ... and studies the major market drivers, threats, opportunities, ... data tables and 64 figures spread through 225 ...
Breaking Medicine Technology:AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4
(Date:9/22/2014)... 2014 (HealthDay News) -- All sexually active women ... common sexually transmitted infections: chlamydia and gonorrhea, according ... Task Force. The task force noted ... 24 years of age and pregnant women. ... noticeable symptoms. As a result, many infections go ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 (HealthDay ... months and older be vaccinated for the upcoming flu season. ... recommendations to advise that the youngest kids should have two ... wants parents of children aged 2 to 8 to consider ... flu shot if it,s readily available. "It,s important to ...
(Date:9/22/2014)... have found that an anticonvulsant drug may help in ... dozens of antibiotics target what bacteria do, their study ... are created, and they found there is a way ... as there is growing concern worldwide about how antibiotic ... World Health Organization has declared that antibiotic resistance is ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Quincy ... the United States, promotes National Self-Improvement Month ... that all individuals should have access to self-improvement ... aging. , The demand for products that preserve ... than ever before. For over six years, Quincy ...
(Date:9/22/2014)... 22, 2014 (HealthDay News) -- Scans of young ... to read. This finding could potentially allow doctors ... difficulties early on, preliminary research suggests. "Early ... with dyslexia as well as most neurodevelopmental disorders," ... associate professor of child and adolescent psychiatry at ...
Breaking Medicine News(10 mins):Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Quincy Bioscience Promotes National Self-Improvement Month 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2
... working at the Swiss Institute for Experimental Cancer Research ... discovered that telomeres, the repeated DNA-protein complexes at the ... cell divides, also contain RNA. This discovery, published online ... understanding of how telomeres function, and may provide a ...
... Success of 2007 National IPF Awareness Week on ... Deadly Lung Disease, SAN JOSE, Calif., Oct. ... announced that the success of its fifth,annual National ... 60,members of Congress about the critical need to ...
... Oct. 4 The following statement was issued,today by ... and Janet,Jenner & Suggs, LLC: Out of public ... million,pound recall of potentially E. coli contaminated ground beef ... & SUGGS, LLC.,have established a registry for victims of ...
... Academy of General,Dentistry (AGD) was extremely disappointed by ... Health Insurance Program (SCHIP),reauthorization bill. The SCHIP bill ... included many important and beneficial dental,provisions intended to ... However, President Bush, who had threatened to veto ...
... provide tobacco cessation services for three more years, ... beBetter,Networks, Inc. (beBetter) has been awarded the West ... Health and Human Resources,for the Bureau for Public ... As the original vendor for the Quitline, beBetter ...
... canola,oil for common dietary fats in the U.S. ... and plant omega-3 fats,noted a modeling study published ... the American Dietetic Association (JADA). The study examined ... oils and canola oil-based,margarine for other margarines and ...
Cached Medicine News:Health News:New telomere discovery could help explain why cancer cells never stop dividing 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 2Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 3Health News:CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget 4Health News:Establishment of Topps Meat Recall Registry for Victims of E. Coli Poisoning 2Health News:Establishment of Topps Meat Recall Registry for Victims of E. Coli Poisoning 3Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 2Health News:AGD Concerned With Presidential Veto of SCHIP Reauthorization Bill 3Health News:beBetter Awarded WV Quitline Contract 2Health News:Canola Oil Can Help Americans Meet Dietary Fat Recommendations 2
... Safety Knife with BD Xstar Blade includes ... protects the blade in prodedure and handling. ... on a grind-less process for manufacturing surgical ... sharpness and consistency. The arch style, ...
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
... The BD Safety Knife with BD ... retractable shield that protects the blade in ... technology is based on a grind-less process ... process yields outstanding sharpness and consistency. ...
Bio-Rad's Genetic Systems HIV-1/HIV-2 PLUS O EIA is a unique assay that detects the broadest range of HIV....
Medicine Products: